NGL Fine Chem Ltd

AI

NGL Fine Chem Ltd

₹ 2,900 -4.65%
16 Nov - close price
About

Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health.[1]

Key Points

Business Overview:[1][2]
NGLFCL primarily manufactures veterinary pharmaceutical APIs and intermediates, catering to the antiprotozoal and anthelmintic therapeutic segments. Its products are used in the animal healthcare industry.

Product Profile:[3][4]
NGL Fine-Chem offers 45 APIs (43 veterinary and 2 human APIs), 1 intermediate and 11 finished dosage forms. Its veterinary API portfolio covers anthelmintics, ectoparasiticides, antiprotozoals, and phosphorus supplements, supported by custom synthesis and R&D capabilities.

  • Market Cap ₹ 1,793 Cr.
  • Current Price ₹ 2,900
  • High / Low ₹ 3,602 / 1,261
  • Stock P/E 28.1
  • Book Value ₹ 587
  • Dividend Yield 0.06 %
  • ROCE 18.6 %
  • ROE 17.4 %
  • Face Value ₹ 5.00

Pros

  • Company is expected to give good quarter

Cons

  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
80 88 100 91 93 89 95 104 120 128 149 139 159
66 74 84 81 82 84 89 93 103 105 128 116 131
Operating Profit 14 14 16 9 12 5 6 11 17 22 21 23 28
OPM % 17% 16% 16% 10% 12% 6% 7% 11% 14% 18% 14% 17% 18%
3 4 4 6 5 -0 -1 6 2 5 2 7 1
Interest 0 0 0 0 0 1 1 1 1 1 1 1 1
Depreciation 3 3 3 3 3 3 3 4 5 5 5 5 7
Profit before tax 14 14 16 12 13 1 1 12 13 21 18 24 22
Tax % 25% 30% 23% 22% 26% -1% 49% 22% 26% 24% 24% 25% 25%
10 10 12 9 10 1 1 9 10 16 13 18 16
EPS in Rs 16.96 16.24 19.94 14.92 15.88 2.07 0.87 14.96 15.59 25.40 21.84 29.78 26.30
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
88 96 100 114 153 152 258 318 278 339 368 501 575
73 74 74 92 121 130 178 249 243 285 333 421 480
Operating Profit 15 22 25 22 32 22 80 68 35 54 35 80 95
OPM % 17% 23% 26% 19% 21% 14% 31% 21% 13% 16% 10% 16% 17%
2 0 1 3 4 1 8 11 6 14 8 8 16
Interest 2 2 1 2 3 3 2 2 2 2 3 5 4
Depreciation 3 3 3 5 6 8 8 10 11 12 12 20 22
Profit before tax 13 18 23 18 28 12 78 67 27 54 28 63 85
Tax % 35% 36% 35% 29% 27% 31% 27% 25% 25% 24% 24% 24%
8 11 15 13 20 8 57 50 20 41 21 48 64
EPS in Rs 13.48 18.45 24.10 20.38 32.58 13.50 91.81 80.77 33.18 66.88 34.19 77.91 103.32
Dividend Payout % 0% 0% 0% 0% 5% 13% 2% 2% 5% 3% 5% 2%

(S): Standalone figures, shown where consolidated figures are not available.

Compounded Sales Growth
10 Years: %
5 Years: 14%
3 Years: 22%
TTM: 41%
Compounded Profit Growth
10 Years: %
5 Years: -1%
3 Years: 37%
TTM: 209%
Stock Price CAGR
10 Years: 27%
5 Years: 1%
3 Years: 14%
1 Year: 109%
Return on Equity
10 Years: %
5 Years: 15%
3 Years: 14%
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 3 3 3 3 3 3 3 3 3 3 3 3 3
Reserves 30 41 56 69 89 96 151 200 219 260 279 326 360
13 14 23 27 27 28 16 30 32 34 78 123 127
21 19 20 31 23 26 36 44 32 59 75 94 138
Total Liabilities 67 78 102 129 142 154 207 277 287 356 435 545 628
17 24 25 56 61 68 64 89 88 86 143 164 291
CWIP 1 2 16 3 0 0 12 6 26 46 50 95 0
Investments 2 3 6 6 9 11 29 29 39 54 60 39 39
46 49 55 63 73 75 102 153 133 171 183 247 298
Total Assets 67 78 102 129 142 154 207 277 287 356 435 545 628

(S): Standalone figures, shown where consolidated figures are not available.

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
8 8 10 22 9 20 27 14 35 20 32 43
-3 -10 -10 -21 -10 -20 -25 -14 -27 -27 -70 -71
-4 2 0 0 0 -1 -1 -1 -1 -1 37 30
Net Cash Flow 1 0 -0 1 -1 -0 2 -1 7 -7 0 2
Free Cash Flow 5 -2 -8 -1 -6 6 10 -15 5 -8 -41 -43
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 80% 68% 70% 128% 50% 110% 60% 45% 121% 62% 111% 73%

(S): Standalone figures, shown where consolidated figures are not available.

Ratios

Consolidated / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 107 123 110 89 79 63 53 74 86 97 82 95
Inventory Days 106 90 114 134 106 155 132 137 69 98 101 106
Days Payable 150 122 139 187 92 116 103 91 63 112 103 97
Cash Conversion Cycle 63 91 85 35 93 102 82 120 93 83 81 104
Working Capital Days 38 49 45 18 70 58 69 90 68 76 50 60
ROCE % 29% 37% 34% 22% 14% 54% 34% 12% 20% 10% 19%

(S): Standalone figures, shown where consolidated figures are not available.

Insights

In beta
Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Number of APIs in product portfolio
APIs

Log in to view insights

Please log in to see hidden values.

Login
Number of customers
customers
Stainless steel reactor capacity
KL
Top 10 customers as % of sales
%
Top 10 products as % of sales
%
Animal API share of revenue
%
Asia revenue share
%
Cumulative Greenfield expansion capex incurred
INR crores
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
73.06% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.73% 72.49% 72.49%
0.04% 0.10% 0.03% 0.02% 0.05% 0.00% 0.00% 0.00% 0.00% 0.03% 0.05% 0.04%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.00%
26.91% 27.16% 27.24% 27.25% 27.23% 27.26% 27.26% 27.26% 27.26% 27.23% 27.43% 27.46%
No. of Shareholders 16,41015,04114,60814,57514,11014,38614,01013,38712,83412,51613,39312,939

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls